A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei

Pseudomyxoma peritonei (PMP) is a rare neoplastic process characterised by progressive intra-abdominal dissemination of mucinous tumour, and generally considered resistant to systemic chemotherapy. A phase II study in patients with advanced unresectable PMP was undertaken to evaluate the combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Farquharson, A L, Pranesh, N, Witham, G, Swindell, R, Taylor, M B, Renehan, A G, Rout, S, Wilson, M S, O'Dwyer, S T, Saunders, M P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527821/
https://www.ncbi.nlm.nih.gov/pubmed/18682713
http://dx.doi.org/10.1038/sj.bjc.6604522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527821/
https://www.ncbi.nlm.nih.gov/pubmed/18682713
http://dx.doi.org/10.1038/sj.bjc.6604522

Ejemplares similares